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The treatment of non-small cell lung cancer (NSCLC) andsmall cell lung cancer (SCLC) has reached a plateau of
effectiveness with doublet chemotherapy. Profound re-
sponses are observed with anti-epidermal growth factor re-
ceptor (EGFR) tyrosine kinase and anaplastic lymphoma
kinase inhibitors in patients with EGFR-activating muta-
tions and EML-4-anaplastic lymphoma kinase gene fusion,
respectively. Patients eventually will develop disease pro-
gression. With an increased understanding of the biology
of lung cancer, its molecular complexity has become very
apparent, and curing this disease with current conventional
treatments is highly unlikely. One hypothesis, discussed in
an introductory talk by Dr. Rudin, is that this is due to the
existence of cancer stem cells (CSCs) within a tumor
population.1 Putative CSCs have been described in a vari-
ety of hematologic and solid tumors including lung can-
cer.2 Many questions are still unresolved in this challeng-
ing field. Extensive characterization of murine CSC
models have not yet found their human counterpart for all
tumor types. CSC markers still need to be properly defined
and validated. The true origin of CSC is still unclear, and
the ability to define a CSC niche and how it is regulated is
very complex. More than one CSC type with different
phenotypes per tumor type is likely. Murine models of
lung adenocarcinomas have shown the importance of the
tumor genotype in defining the type of lung cancer prop-
agating cell and the implications of CSC heterogeneity for
cancer treatment.3
Embryonic signaling pathways (ESPs) such as Hedge-
hog (Hh), Notch, Wnt, and Bmi-1 are fundamental in normal
stem-cell development and organogenesis. These same path-
ways are also involved in driving CSC activity.4 The first
presentation of this session by Dr. Rudin focused on the CSC
model and the role of some of the ESP in lung cancer.
Subsequent presentations by Dr. Rudin, Dr. Weiss, and Dr.
van Tournout focused on the development of novel agents
that target the Hh pathway, and Dr. Camidge and Dr. Stewart
discussed novel agents targeting the Notch pathway, to pos-
sibly eliminate lung CSC.
SUMMARY OF PRESENTATIONS
CSCs and ESPs
Dr. Rudin presented an overview of the rationale behind
the CSC hypothesis and targeting the ESP. The CSC hypothesis
suggests that within the bulk population of tumor cells, there is
a small fraction of cells with stem-cell characteristics that drive
andmaintain cancer growth.1,2 Clinical responses may reflect the
targeting of the bulk nonstem-cell population by current stan-
dard therapies; however, relapse and ultimately survival may be
determined by the behavior of the more resistant CSC popula-
tion. This population is driven by ESP and targeting of these
pathways could result in increased likelihood of cures. Bmi-1
has a role in lung tumorigenesis and bronchioloalveolar stem-
cell expansion, and the transcription factor ASCL1 in SCLC
carcinogenesis. Sonic Hh signaling is critical in normal lung
development, lung injury repair, and lung carcinogenesis. This
pathway is dysregulated differently depending on the tumor
type. The activity of the Hh pathway in SCLC seems to occur
mainly by either a paracrine or autocrine mechanism contrary to
the presence of activating mutations observed in other tumors.5
Hh pathway blockade can suppress clonogenicity and xenograft
tumor growth in different preclinical models of hematologic and
solid tumors. Dr. Rudin emphasized the clinical benefit already
observed in basal cell carcinoma (BCC)6 and discussed his
ongoing study in SCLC E1508, a three-arm randomized phase 2
study of cisplatin/etoposide with or without Hh inhibitor GDC-
0499 or the type 1 insulin-like growth factor receptor monoclo-
nal antibody A12 (Figure 1).
Hunting the Hedgehog Pathway: The
Genentech GDC-0449 Experience
Dr. Weiss summarized the role of the Hh pathway in
cancer and the clinical development of the first Hh inhibitor.
Abnormal activation of the Hh pathway occurs in nearly every
type of cancer. Hh signaling has an important role in maintaining
the CSC in different hematologic and solid malignancies. The
pathway can be inhibited directly in tumor cells, in the stroma
supporting tumor growth and possibly directly in the CSC.
Mutations in PTCH or Smoothened (SMO) are involved in the
tumorigenesis of BCC. Cyclopamine is a naturally occurring
inhibitor of SMO. This finding led to the development of
GDC-0449, a synthetic oral inhibitor of SMO that has demon-
strated significant clinical activity with a good toxicity profile in
patients with metastatic BCC.6 Potential toxicities due to the
chronic use of this agent remain to be evaluated. Several phase
II studies in different tumor types with GDC-0449 at 150 mg
once daily are currently underway.
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IPI-926: Preclinical and Clinical Update
Dr. Rudin summarized the preclinical and clinical de-
velopment of IPI-926, another potent oral inhibitor of SMO.
IPI-926 delays tumor recurrence postcytoreduction in xeno-
graft models of SCLC and NSCLC. It can also suppress the
increase of transcription factor Gli-1 in tumor stroma induced
after chemotherapy. Most importantly, IPI-926 inhibits tumor
take in SCLC serial transplant models suggesting that CSC
are being targeted.7 A phase I study of IPI-926 is ongoing
with three expansion cohorts at the maximum tolerated dose
for BCC, medulloblastoma and chondrosarcoma, and solid
tumors. Results are expected for late 2010.
Notch Signaling Pathway—-Secretase
Inhibitors
Dr. Camidge discussed the development of RO4929097, a
potent and selective inhibitor of -secretase (GSI).8 Gamma
secretase is a membrane-associated protease complex critical
for the activation of the Notch pathway. Inhibition of Notch
signaling inhibits tumor growth, affects angiogenesis, and
inhibits CSC. RO4929097 reduces the expression of the
Notch target Hes-1 in A549 lung cancer cells, induces a less
transformed phenotype, inhibits soft agar growth, and affects
tumor growth in lung cancer xenografts. Different oral regi-
mens are currently being tested in phase 1. Dr. Stewart
presented data from his group at MD Anderson. Chemother-
apy can select for the presence of cells with CSC features,
and the role of Notch in NSCLC. Notch, Notch ligand, and
Hes1 and Hey1 transcription factors are commonly expressed
in NSCLC cells. Hypoxia can increase Notch 1 expression.
Notch signaling is increased in ALDH and CD133
NSCLC stem cells. Notch 3 expression is increased in both
adenocarcinoma and squamous histologies. EGFR-mutant
NSCLC cell lines have increased activity of the Notch path-
way. Dr. Stewart also summarized the development of
PF03084014, another GSI with preclinical activity in NSCLC
and other tumors.9 Phase 1 studies are underway in solid
tumors and in acute lymphoblastic leukemia. Two CTEP-
funded trials in NSCLC are soon to be initiated at MD
Anderson: a phase 1 study of RO-GSI in combination with
erlotinib and a phase 2 study of RO-GSI as consolidation for
nonprogressors after first-line chemotherapy.
FUTURE DIRECTIONS
Several challenges lie ahead to successfully translate
CSC and ESP targeting into the clinic. Further character-
ization of human lung CSC and proper validation of CSC
markers along with adequate assay development are
needed. Studying cross-talk with non-CSC and the tumor
microenvironment will be important. A number of drugs
targeting ESP are under development. An improved
knowledge of the role of ESP in lung CSC function and an
understanding of how key pathways in lung cancer (i.e.,
EGFR, Ras, and P53) affect or are affected in this context
will be critical. These therapies need to be tested in the
appropriate patient population and with the use of adequate
pharmacodynamic markers. The combined targeting of different
CSC pathways, combinations with other targeted therapies
and/or chemotherapy, and the right clinical setting (i.e., minimal
residual disease) where to test these approaches are all areas that
remain to be explored further.
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